Skip to main content

What the FDA labels say about taking them together

Cladribine and doravirine/islatravir

Doravirine/islatravir's FDA label of April 20, 2026 names cladribine in its drug interactions section; the cladribine label PlainMeds reads does not name doravirine/islatravir. The doravirine/islatravir label: “Co-administration with these nucleoside antimetabolites is not recommended as dCK substrates may cause a decrease in the intracellular concentration of ISL-TP.”

Check it at the source: the cladribine FDA label on DailyMed (effective May 27, 2026, EMD Serono, Inc.); the doravirine/islatravir FDA label on DailyMed (effective April 20, 2026, Merck Sharp & Dohme LLC).

What does the cladribine label say about doravirine/islatravir?

Cladribine's label (effective May 27, 2026) does not name doravirine/islatravir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Mavenclad), EMD Serono, Inc., effective May 27, 2026 (SPL set 9c75e30a-a410-40f1-b653-04d532bd9144), via openFDA; the full label on DailyMed

What does the doravirine/islatravir label say about cladribine?

Doravirine/islatravir label, drug interactions

Concomitant Drug Class/Drug Name: Nucleoside Antimetabolites cladribine clofarabine cytarabine fludarabine gemcitabine; Effect on Concentration: ↓ ISL-TP; Clinical Comment: Co-administration with these nucleoside antimetabolites is not recommended as dCK substrates may cause a decrease in the intracellular concentration of ISL-TP.

Source: FDA drug label (IDVYNSO), NDA216964 (Msd), as published by Merck Sharp & Dohme LLC, effective April 20, 2026 (SPL set 11aaeb53-9848-433c-be7f-db8a5bc0b26f), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

6Cladribine generic labelers
0Doravirine/islatravir generic labelers
CladribineDoravirine/islatravir
Labeled forMultiple sclerosis, Leukemia, lymphoma and myelomaHIV
Boxed warningYesNo
Pharmacy cost (NADAC)n/an/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?